Literature DB >> 23597792

Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).

Narsimha Reddy Penthala1, Purushothama Rao Ponugoti, Justin R Nickell, Agripina G Deaciuc, Linda P Dwoskin, Peter A Crooks.   

Abstract

Central heterocyclic ring size reduction from piperidinyl to pyrrolidinyl in the vesicular monoamine transporter-2 (VMAT2) inhibitor GZ-793A and its analogs resulted in novel N-propane-1,2(R)-diol analogs 11a-i. These compounds were evaluated for their affinity for the dihydrotetrabenazine (DTBZ) binding site on VMAT2 and for their ability to inhibit vesicular dopamine (DA) uptake. The 4-difluoromethoxyphenethyl analog 11f was the most potent inhibitor of [(3)H]-DTBZ binding (Ki=560 nM), with 15-fold greater affinity for this site than GZ-793A (Ki=8.29 μM). Analog 11f also showed similar potency of inhibition of [(3)H]-DA uptake into vesicles (Ki=45 nM) compared to that for GZ-793A (Ki=29 nM). Thus, 11f represents a new water-soluble inhibitor of VMAT function.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23597792      PMCID: PMC3725993          DOI: 10.1016/j.bmcl.2013.03.092

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

1.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

2.  Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats.

Authors:  Dennis K Miller; Steven B Harrod; Thomas A Green; Mei-Yee Wong; Michael T Bardo; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2003-01       Impact factor: 3.533

3.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake.

Authors:  L Teng; P A Crooks; P K Sonsalla; L P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

5.  Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Authors:  David B Horton; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2011-07-21       Impact factor: 4.030

6.  Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Seth D Norrholm; Peter A Crooks
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

7.  Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.

Authors:  Guangrong Zheng; David B Horton; Narsimha Reddy Penthala; Justin R Nickell; John P Culver; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Medchemcomm       Date:  2013-03       Impact factor: 3.597

8.  Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).

Authors:  Ashish P Vartak; Justin R Nickell; Jaturaporn Chagkutip; Linda P Dwoskin; Peter A Crooks
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

9.  Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Sairam Krishnamurthy; Seth Norrholm; Gabriela Deaciuc; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

10.  Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2008-10-14       Impact factor: 2.823

View more
  6 in total

1.  Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.

Authors:  Derong Ding; Justin R Nickell; Agripina G Deaciuc; Narsimha Reddy Penthala; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2013-08-11       Impact factor: 3.641

Review 2.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

3.  Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Derong Ding; Justin R Nickell; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2015-05-09       Impact factor: 2.823

4.  Study of Vesicular Monoamine Transporter 2 in Myopic Retina Using [18F]FP-(+)-DTBZ.

Authors:  Yu Sun; Ning Zhao; Wangyuan Liu; Miao Liu; Zizhao Ju; Jun Li; Zhen Cheng; Xingdang Liu
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

5.  Synthesis of Lobeline, Lobelane and their Analogues. A Review.

Authors:  Guangrong Zheng; Peter A Crooks
Journal:  Org Prep Proced Int       Date:  2015-08-17       Impact factor: 1.628

6.  A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2.

Authors:  Zih-Rou Huang; Chia-Ling Tsai; Ya-Yao Huang; Chyng-Yann Shiue; Kai-Yuan Tzen; Ruoh-Fang Yen; Ling-Wei Hsin
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.